Logos Capital is a fundamental biotechnology-focused fund that seeks to combine in-house data analytics with scientific and clinical expertise to identify transformative therapies in healthcare.
Employees: 1-10
Investment Stage: Series B
Portfolio 61
| Date | Name | Website | Total Raised | Location |
| 29.03.2026 | Pinnacle M... | pinnaclemedicines.com | $89M | United Sta... |
| 13.01.2026 | Mirador Th... | miradortx.com | $250M | United Sta... |
| 16.11.2025 | Beacon Bio... | beacon.bio | $113M | United Sta... |
| 07.08.2023 | Gracell Bi... | gracellbio.com | $250M | China, Jia... |
| 11.07.2023 | @Septerna_... | septerna.com | $290M | United Sta... |
| 17.10.2022 | Odyssey Th... | odysseytx.com | $487M | United Sta... |
| 27.08.2021 | Willow | onewillow.com | - | - |
| 17.08.2021 | Nuvalent | nuvalent.com | $187.23M | United Sta... |
| 17.08.2021 | Ventyx Bio... | ventyxbio.com | $165M | United Sta... |
| 17.08.2021 | Graphite B... | graphitebio.com | $195.75M | United Sta... |
Show more
Persons 9
| Date | First Name | Last Name | Title | Location | |||
| - | Cynthia | (Cindy) Go... | Director o... | - | - | - | |
| - | Bonny | Chen | Sr. Lead, ... | - | - | - | |
| - | Dr. | Graham Wal... | General Pa... | - | - | - | |
| - | Udit | Dalal | VP, Operat... | - | - | - | |
| - | Elana | Sears | Head of Ma... | - | - | - | |
| - | Dr. | Yuqi Wang,... | Analyst | - | - | - | |
| - | Dr. | Ed Zhong, ... | General Pa... | - | - | - | |
| - | Derek | Gould, JD | General Co... | - | - | - | |
| - | Dr. | Arsani Wil... | Managing P... | - | - | - |
Mentions in press and media 27
| Date | Title | Description |
| 10.08.2026 | Expedition Therapeutics Closes $115 Million Series B | SAN FRANCISCO, CA, Expedition Therapeutics, a clinical-stage biotechnology company developing novel oral small molecule therapies for inflammatory and respiratory diseases, announced the closing of an oversubscribed $115 million Series B f... |
| 09.08.2026 | Expedition Therapeutics Lands $115M Series B | SAN FRANCISCO, CA, Expedition Therapeutics has announced the closing of an oversubscribed $115 million Series B financing round. >> Click here for more funding data on Expedition Therapeutics >> To export Expedition Therapeutic... |
| 30.03.2026 | Pinnacle Medicines Secures $89M Series B: Oral Peptides Advance Clinical Pipeline with AI Power | Pinnacle Medicines, a Doylestown, PA biotech, closed an oversubscribed $89 million Series B funding round. This significant capital injection accelerates its oral peptide therapeutics pipeline. The company targets immunology and cardiometab... |
| 29.03.2026 | Pinnacle Medicines: $89 Million Series B Raised For Oral Peptide Therapeutics Development | Pinnacle Medicines, a biotechnology company focused on oral peptide therapeutics, announced it has closed an oversubscribed $89 million Series B financing round to advance its pipeline into clinical trials. The round was co-led by LAV and F... |
| 23.02.2026 | Sensei Biotherapeutics Acquires Faeth Therapeutics And Raises $200 Million In Private Placement | Sensei Biotherapeutics announced it has acquired Faeth Therapeutics and secured approximately $200 million in gross proceeds through a concurrent private placement, positioning the combined company to advance its oncology pipeline through k... |
| 14.01.2026 | Mirador Therapeutics Secures $250M, Accelerates Precision Medicine | Mirador Therapeutics secured $250M in Series B funding. This propels their innovative precision medicine strategy. Total capital raised now exceeds $650M. The San Diego firm targets immune-mediated inflammatory and fibrotic diseases. Funds ... |
| 13.01.2026 | Mirador Raises $250M in Series B Funding | Mirador Therapeutics, a San Diego, CA-based clinical-stage precision medicine company developing new therapies for immune-mediated inflammatory and fibrotic diseases, raised $250M in Series B funding. Backers included T. Rowe Price Investme... |
| 11.01.2026 | Diagonal Therapeutics Secures $125M to Propel Innovative Antibody Therapies | Diagonal Therapeutics secured $125M Series B funding. This advances DIAG723, a first-in-class clustering antibody. It targets hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH). The Watertown biotech corre... |
| 11.01.2026 | Diagonal Therapeutics: $125 Million Series B Raised To Advance DIAG723 Clustering Antibody Into the Clinic | Diagonal Therapeutics announced it has raised $125 million in an oversubscribed Series B financing to advance its lead program, DIAG723, a first-in-class “clustering antibody” designed to correct dysregulated receptor signaling implicated i... |
| 09.01.2026 | Diagonal Therapeutics Raises $125M in Series B Financing | Diagonal Therapeutics, a Watertown, MA-based biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, raised $125M in Series B Funding. The round was co-led by ... |
Show more